Prodrug for tumor therapy
Scientists of the University of Göttingen developed new highly potent drugs (with an IC50 in the pico-Molar range) as well as a selective tumor therapy through their prodrugs based on the Antibody Directed Enzyme Prodrug Therapy (ADEPT). Selective is achieved by the specific tumor targeting through the antibody. The highly soluble prodrugs are activated into the cytotoxic drugs only at tumor site through the enzyme, which is coupled to the antibody. While prodrugs have a low cytotoxicity, active drugs show an unbelievable cytotoxicity in the pico-molar range, much higher than actually used Doxorubicin. The drugs could be used equivalent to current chemotherapeutic agents or combined with e.g. a targeting-antibody.
We are now looking for companies, which are interested in licensing, developing and commercializing our approach.
Further Information: PDF
MBM ScienceBridge GmbH
Phone: (0551) 30724-152
Contact
Dr. Jens-Peter Horst
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Microscopic basis of a new form of quantum magnetism
Not all magnets are the same. When we think of magnetism, we often think of magnets that stick to a refrigerator’s door. For these types of magnets, the electronic interactions…
An epigenome editing toolkit to dissect the mechanisms of gene regulation
A study from the Hackett group at EMBL Rome led to the development of a powerful epigenetic editing technology, which unlocks the ability to precisely program chromatin modifications. Understanding how…
NASA selects UF mission to better track the Earth’s water and ice
NASA has selected a team of University of Florida aerospace engineers to pursue a groundbreaking $12 million mission aimed at improving the way we track changes in Earth’s structures, such…
